Search results
Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
Zacks· 4 days agoFree Report) closed the most recent trading day at $78.99, moving +1.24% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.11%. Coming into today, shares of ...
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 1 day agoThe Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, signed a Memorandum of Understanding (MoU) with AstraZeneca during BIO International ...
3 No-Brainer Stocks to Buy in June | The Motley Fool
The Motley Fool· 4 days agoYou're probably familiar with the old adage, "April showers bring May flowers." Here's why they picked AbbVie (ABBV 3.15%), AstraZeneca (AZN 1.63%), and...
AstraZeneca immunotherapy extends survival by two years in rarer type of lung cancer
BioPharma Dive via Yahoo Finance· 5 days agoAstraZeneca’s immunotherapy Imfinzi helped people in the early stages of a type of lung cancer live...
ASCO24: Tagrisso in the spotlight, Caribou’s adjustment and Lilly’s KRAS competitor
BioPharma Dive via Yahoo Finance· 3 days agoAstraZeneca’s therapy could see wider use after ASCO data. Elsewhere, Caribou sought to explain an...
EMA CHMP recommends AstraZeneca’s Tagrisso for lung cancer
Pharmaceutical Technology via Yahoo Finance· 3 days agoThe Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...
3 No-Brainer Stocks to Buy in June
Motley Fool via Yahoo Finance· 4 days agoBut what does June bring? Three Motley Fool contributors think the new month should usher in great investing opportunities. Here's why they picked AbbVie...
Veeva R&D Summit: Pharma companies need a say in AI regulation
Clinical Trials Arena via Yahoo Finance· 12 hours agoSenderovitz is working with partners from other pharmaceutical companies, including James...
AstraZeneca (NASDAQ:AZN) Now Covered by Analysts at The Goldman Sachs Group
ETF DAILY NEWS· 7 days agoThe Goldman Sachs Group assumed coverage on shares of AstraZeneca (NASDAQ:AZN – Free Report) in a research report report published on Thursday morning, Marketbeat Ratings ...
Ionis Pharmaceuticals (IONS) Down 0.7% Since Last Earnings Report: Can It Rebound?
Zacks via Yahoo Finance· 6 hours agoIn the first quarter, Wainua royalty revenues were $1 million. Wainua generated sales of $5 million...
